-
Something wrong with this record ?
Serum neurofilament levels in patients with multiple sclerosis: A comparison of SIMOA and high sensitivity ELISA assays and contributing factors to ELISA levels
KZ. Revendova, D. Zeman, R. Bunganic, K. Karasova, O. Volny, M. Bar, P. Kusnierova
Language English Country Netherlands
Document type Journal Article
- MeSH
- Biomarkers MeSH
- Enzyme-Linked Immunosorbent Assay MeSH
- Intermediate Filaments * MeSH
- Humans MeSH
- Multiple Sclerosis * diagnosis MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic MeSH
BACKGROUND: Serum neurofilaments (sNfs), especially the most investigated serum neurofilament light chain (sNfL), are promising biomarkers in multiple sclerosis (MS). However, their clinical utility is still limited, given the availability and costs of accessible analytical methods. The gold standard for the detection of sNfs is represented by the single molecule arrays (SIMOA). Recently, a high sensitivity enzyme-linked immunosorbent assay (hsELISA) has also been introduced. The objective of the study was to compare both assays for the determination of sNfL and neurofilament heavy chain (sNfH) concentrations in a defined MS cohort. The second objective was to identify contributing factors to sNfs concentrations determined by hsELISA. METHODS: Serum samples were collected from MS patients attending the MS Centre, University Hospital Ostrava, Czech Republic. The levels of sNfs were detected using SIMOA and hsELISA assays. RESULTS: The Spearman's rank correlation coefficient between the sNfL SIMOA and sNfL hsELISA and between the sNfH SIMOA and sNfH hsELISA was moderate rs= 0.543 (p = 0.001) and rs= 0.583 (p = 0.001), respectively. The Passing-Bablok regression analysis demonstrated bias between both methods. Equally significant bias between the methods was confirmed by the Bland-Altman plots. Furthermore, confounding factors affecting the sNfL levels were glomerular filtration rate (eGFR; 95% CI -2.34 to -0.04) and sex (95% CI -2.38 to -0.10). The sNfH levels were affected by age (95% CI 0.01 to 0.07), eGFR (95% CI -2.45 to -0.02), body mass index (BMI; 95% CI -0.31 to -0.05), and blood volume (95% CI 0.69 to 3.35). CONCLUSION: This analytical study showed significant differences between hsELISA and SIMOA methods, especially for the sNfH concentrations. We identified confounding factors for sNfs levels determined by hsELISA. The sNfs levels were influenced by renal function and sex, whilst sNfH levels were affected by age, BMI, and total blood volume.
Department of Clinical Neurosciences University of Ostrava Ostrava Czech Republic
Department of Neurology University Hospital Ostrava Ostrava Czech Republic
Institute of Laboratory Medicine University Hospital Brno Brno Czech Republic
Institute of Laboratory Medicine University of Ostrava Ostrava Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032829
- 003
- CZ-PrNML
- 005
- 20230131151817.0
- 007
- ta
- 008
- 230120s2022 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.msard.2022.104177 $2 doi
- 035 __
- $a (PubMed)36130459
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Revendova, K Zondra $u Department of Neurology, University Hospital Ostrava, Ostrava, Czech Republic; Department of Clinical Neurosciences, University of Ostrava, Ostrava, Czech Republic
- 245 10
- $a Serum neurofilament levels in patients with multiple sclerosis: A comparison of SIMOA and high sensitivity ELISA assays and contributing factors to ELISA levels / $c KZ. Revendova, D. Zeman, R. Bunganic, K. Karasova, O. Volny, M. Bar, P. Kusnierova
- 520 9_
- $a BACKGROUND: Serum neurofilaments (sNfs), especially the most investigated serum neurofilament light chain (sNfL), are promising biomarkers in multiple sclerosis (MS). However, their clinical utility is still limited, given the availability and costs of accessible analytical methods. The gold standard for the detection of sNfs is represented by the single molecule arrays (SIMOA). Recently, a high sensitivity enzyme-linked immunosorbent assay (hsELISA) has also been introduced. The objective of the study was to compare both assays for the determination of sNfL and neurofilament heavy chain (sNfH) concentrations in a defined MS cohort. The second objective was to identify contributing factors to sNfs concentrations determined by hsELISA. METHODS: Serum samples were collected from MS patients attending the MS Centre, University Hospital Ostrava, Czech Republic. The levels of sNfs were detected using SIMOA and hsELISA assays. RESULTS: The Spearman's rank correlation coefficient between the sNfL SIMOA and sNfL hsELISA and between the sNfH SIMOA and sNfH hsELISA was moderate rs= 0.543 (p = 0.001) and rs= 0.583 (p = 0.001), respectively. The Passing-Bablok regression analysis demonstrated bias between both methods. Equally significant bias between the methods was confirmed by the Bland-Altman plots. Furthermore, confounding factors affecting the sNfL levels were glomerular filtration rate (eGFR; 95% CI -2.34 to -0.04) and sex (95% CI -2.38 to -0.10). The sNfH levels were affected by age (95% CI 0.01 to 0.07), eGFR (95% CI -2.45 to -0.02), body mass index (BMI; 95% CI -0.31 to -0.05), and blood volume (95% CI 0.69 to 3.35). CONCLUSION: This analytical study showed significant differences between hsELISA and SIMOA methods, especially for the sNfH concentrations. We identified confounding factors for sNfs levels determined by hsELISA. The sNfs levels were influenced by renal function and sex, whilst sNfH levels were affected by age, BMI, and total blood volume.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a intermediární filamenta $7 D007382
- 650 12
- $a roztroušená skleróza $x diagnóza $7 D009103
- 650 _2
- $a biologické markery $7 D015415
- 650 _2
- $a ELISA $7 D004797
- 651 _2
- $a Česká republika $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Zeman, D $u Institute of Laboratory Medicine, University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Bunganic, R $u Department of Neurology, University Hospital Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Karasova, K $u Institute of Laboratory Medicine, University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Volny, O $u Department of Neurology, University Hospital Ostrava, Ostrava, Czech Republic; Department of Clinical Neurosciences, University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Bar, M $u Department of Neurology, University Hospital Ostrava, Ostrava, Czech Republic; Department of Clinical Neurosciences, University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Kusnierova, P $u Institute of Laboratory Medicine, University of Ostrava, Ostrava, Czech Republic; Department of Clinical Biochemistry, Institute of Laboratory Medicine, University Hospital Ostrava, Ostrava, Czech Republic. Electronic address: pavlina.kusnierova@fno.cz
- 773 0_
- $w MED00188780 $t Multiple sclerosis and related disorders $x 2211-0356 $g Roč. 67, č. - (2022), s. 104177
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36130459 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131151813 $b ABA008
- 999 __
- $a ok $b bmc $g 1891519 $s 1184164
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 67 $c - $d 104177 $e 20220911 $i 2211-0356 $m Multiple sclerosis and related disorders $n Mult Scler Relat Disord $x MED00188780
- LZP __
- $a Pubmed-20230120